Pune: FDA Seizes Medicines Worth Rs 1.72 Crore From PCMC’s Central Medical Store, Finds Lack of Manufacturing Permissions, Substandard Qualitity Medicines

FDA
Share this News:

Pimpri Chinchwad, 21st November 2026: The Food and Drug Administration (FDA) has seized medicines worth an estimated Rs 1.72 crore from the Pimpri Chinchwad Municipal Corporation’s (PCMC) Central Medical Store at Yashwantrao Chavan Memorial (YCM) Hospital after finding that some drugs supplied to the civic body by a private manufacturer did not have valid manufacturing permissions and others failed prescribed quality standards.

The FDA has also seized an additional stock of medicines worth Rs 17.58 lakh from the manufacturing facility of Inducare Pharmaceuticals and Research Foundation at Jejuri MIDC in Pune district. The total value of the seized stock at both locations is estimated at Rs 1.90 crore, according to an FDA statement.

The action was taken under Section 22(1)(c) of the Drugs and Cosmetics Act, 1940. FDA officials seized 10 categories of medicines from the PCMC’s Central Medical Store, with their estimated market value pegged at Rs 1.72 crore. Some of the samples were declared ‘Not of Standard Quality’ (NSQ), with deficiencies found in assay, dissolution, description, uniformity of weight and labelling.

The FDA also found that the manufacturer did not possess valid product permissions for the manufacture of certain medicines supplied to the civic body. A show-cause notice was issued to the company on October 29, 2026, over the alleged manufacture and supply of medicines without the necessary permissions.

A separate inspection and seizure operation was conducted at the company’s Jejuri factory on October 30, where medicines worth Rs 17.58 lakh were seized. The FDA said it would soon initiate prosecution proceedings against the manufacturer.

Meanwhile, the PCMC clarified that the FDA had not conducted a raid at YCM Hospital and that the civic body had itself approached the FDA for quality testing after receiving complaints about medicines.

According to the civic administration, a complaint regarding the quality of B-Complex with Zinc capsules (CareZinc) was received from its Thergaon hospital on February 14, 2026. The civic body subsequently wrote to the FDA on February 23, requesting it to collect samples and assess the medicines’ quality. The stock had already been withdrawn from use and kept aside.

The FDA report received on July 16 declared the medicine NSQ. Subsequently, on September 8, the PCMC blacklisted Inducare Pharmaceuticals and Research Foundation for three years and barred its supplier, Shree Vinayak Pharma, Pune, from supplying medicines to the civic body for the same period.

The PCMC further said that the FDA had tested 12 types of medicines supplied by Shree Vinayak Pharma on July 27. Of these, 11 were declared NSQ, while two were reported to meet the prescribed quality standards, according to the civic body’s statement.

The FDA took possession of the stock of the 11 medicines on November 4 for further testing and action. The PCMC pegged the value of this stock at Rs 11.95 lakh, disputing reports that medicines worth Rs 1.72 crore had been seized from its store.

The civic body also clarified that no payment had been made to the supplier for the disputed stock.

PCMC health medical officer Dr Laxman Gophane said the civic body had voluntarily approached the FDA to ensure the quality of medicines and patient safety, and reports of an FDA raid at YCM Hospital were factually incorrect.

Additional municipal commissioner Kuldeep Jangam said action had been taken against the manufacturer and supplier based on the FDA’s findings and that the civic body was committed to ensuring the supply of safe and quality medicines.